Items Tagged ‘Ayalew Tefferi’

March 1, 2012

Ruxolitinib in Myelofibrosis: Only for Some Patients

By Mystery User

The first drug ever approved for myelofibrosis, ruxolitinib (Jakafi, Incyte/Novartis), is useful only in about 25% of patients with this disorder, according to Ayalew Tefferi, MD, from the division of hematology at the Mayo Clinic Rochester, Minnesota. Even then, it might not be the best option, he added. Dr. Tefferi was speaking to Medscape Medical […]

View full entry

Tags: Ayalew Tefferi, myelofibrosis, New England Journal of Medicine, ruxolitinib


Contact Us · Privacy Policy